Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues

TOKYO - Japanese pharma Eisai, Daiichi Sankyo and Mitsubishi Tanabe have had a rough seven days despite last week's slate of new drug approvals in Japan. Those approvals were capped with Mitsubishi Tanabe recalls and Eisai's discontinuation of a key Phase III trial